Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes.

The true potential of beta 3-AR agonists in humans can only be evaluated when a compound with good selectivity and efficacy at the human beta 2-AR, coupled with a long duration of action in vivo, has been identified.